Foundayo Stress Urinary Incontinence

• Clarifies that Foundayo is not authorised specifically for stress urinary incontinence
• Explains the separate relationship between weight loss and urinary leakage
• Distinguishes weight-management effects from direct bladder treatment
• Covers established management for stress urinary incontinence

Foundayo and Stress Urinary Incontinence: Can It Help Bladder Leakage?

Foundayo (orforglipron) is an oral GLP-1 medicine authorised in the UK for weight management in eligible adults, as well as for improving glycaemic control in adults with insufficiently controlled type 2 diabetes. It is not authorised specifically to treat stress urinary incontinence (SUI) or bladder leakage.

There is, however, an important distinction. Research is now investigating whether orforglipron could have a role in women with stress urinary incontinence who also have overweight or obesity. A Phase 3 trial called RESTRAIN-SUI is currently recruiting, so this is an area of active research rather than an established treatment indication.

Separately, NICE recommends weight loss for women with urinary incontinence who have a BMI over 30, because weight loss can help urinary symptoms. This does not mean that Foundayo itself is a bladder treatment.

Key things to know about Foundayo and urinary incontinence

• Foundayo contains orforglipron.
• Foundayo is a GLP-1 receptor agonist.
• Foundayo is not specifically authorised for stress urinary incontinence.
• Foundayo should not be described as a medicine for bladder leakage.
• Weight loss can help urinary incontinence in some women living with obesity.
• An improvement associated with weight loss is not the same as Foundayo directly treating the bladder.
• Stress urinary incontinence is a specific type of urinary leakage.
• Supervised pelvic floor muscle training is a first-line treatment for women with stress urinary incontinence.
• Weight loss should not delay other appropriate continence management.
• Foundayo suitability depends on an individual clinical assessment.

Is Foundayo used for stress urinary incontinence?

No. Foundayo is not authorised specifically for stress urinary incontinence. The MHRA authorisation covers weight management in eligible adults and glycaemic control in adults with insufficiently controlled type 2 diabetes, not treatment of urinary leakage.

Foundayo would require clinical trials to determine its effects on bladder function before it could be described as a treatment for stress urinary incontinence, and that means relying on innovative clinical trials supported by relevant clinical trial data rather than assumption.

Someone searching for “Foundayo for stress urinary incontinence” should therefore distinguish the medicine's authorised purpose from possible changes that occur alongside weight loss. Using Foundayo solely as a treatment for stress urinary incontinence would not match the authorised indications described by the MHRA, and no clinical trials have established that use.

Does Foundayo directly treat bladder leakage?

Foundayo should not currently be described as directly treating bladder leakage. The available official UK authorisation does not establish orforglipron as a medicine that directly strengthens the pelvic floor, controls the bladder or treats stress urinary incontinence.

This distinction matters because a symptom can improve during treatment without proving that the medicine directly treated that symptom. If bladder leakage changes while someone is losing weight, weight change and other aspects of continence management may need to be considered separately.

Why is body weight relevant to urinary incontinence?

Body weight can be relevant to urinary incontinence for some people. NICE's pelvic floor dysfunction guidance explains that evidence showed weight loss helped urinary incontinence and overactive bladder in women with a BMI over 30. Foundayo trials have also reported reductions in waist circumference. In one analysis of women in ATTAIN-1, reductions of up to 4.9 inches were reported at 72 weeks. However, this does not establish that the waist reduction itself improves urinary incontinence.

NICE's committee also noted that excess body weight can increase pressure on pelvic floor muscles and organs. This provides a reason why weight management may be considered alongside established continence treatment, but it does not mean body weight is the only factor responsible for urinary leakage.

Can meaningful weight loss improve urinary incontinence?

Yes, weight loss can improve urinary incontinence for some women living with obesity. NICE advises women with urinary incontinence or overactive bladder and a BMI greater than 30 to lose weight.

Importantly, NICE also says other pelvic floor management options should not be delayed while someone loses weight. Weight management is therefore one possible component of care rather than a replacement for treatment specifically aimed at urinary incontinence.

Does weight loss mean Foundayo treats urinary incontinence?

No. Evidence that weight loss can improve urinary incontinence does not establish every weight-management medicine as an incontinence treatment. These are separate claims and should not be combined.

Foundayo may be prescribed for its authorised weight-management indication when an individual meets the relevant clinical criteria. If urinary leakage improves while body weight changes, that improvement cannot automatically be attributed to a direct pharmacological action of Foundayo on the bladder or pelvic floor.

What is stress urinary incontinence?

Stress urinary incontinence is a form of involuntary urine leakage associated with increased pressure on the bladder. Correctly identifying the type of urinary incontinence matters because management differs according to the symptom pattern.

Stress urinary incontinence should also be distinguished from urgency incontinence and mixed urinary incontinence. For example, NICE recommends bladder training as first-line treatment for women with urgency or mixed urinary incontinence, whereas supervised pelvic floor muscle training is central to stress urinary incontinence management.

What treatment is recommended for stress urinary incontinence?

For women with stress urinary incontinence, NICE recommends supervised pelvic floor muscle training as first-line treatment. The programme should be supervised by an appropriately skilled healthcare professional rather than relying solely on unsupervised exercises without assessment.

This is an important distinction for searches such as “Foundayo for bladder leakage”. Foundayo's weight-management role does not replace treatment specifically designed to improve pelvic floor function and manage stress urinary leakage.

Why should bladder leakage be assessed before assuming the cause?

Bladder leakage is not one single condition. Stress urinary incontinence, urgency incontinence and mixed urinary incontinence involve different symptom patterns, and identifying which pattern is present can influence management.

NICE uses bladder diaries as part of urinary incontinence assessment. These can record when urine is passed, leakage episodes, fluid intake and urgency, helping create a clearer picture of the problem. If leakage is new, changing or unexplained, appropriate assessment is more useful than assuming weight loss or Foundayo alone will resolve it.

Can Foundayo replace pelvic floor muscle training?

No. Foundayo should not replace supervised pelvic floor muscle training when that treatment is clinically appropriate for stress urinary incontinence. They address different clinical goals.

NICE continues to recommend supervised pelvic floor muscle training as first-line treatment for stress urinary incontinence, while weight loss may be considered alongside other management where obesity is relevant. A weight-management prescription should therefore not displace established continence care.

What should you monitor if bladder leakage changes while taking Foundayo?

If bladder leakage changes during Foundayo treatment, record the urinary symptoms separately from changes in body weight, even though In the Phase 3 ATTAIN-1 trial, participants receiving the highest studied dose had an average weight loss of 12.4% at 72 weeks. That trial result should not be interpreted as an expected result for every person taking Foundayo.

Useful details include when leakage occurs, what activity was happening at the time, how often episodes happen and whether urgency is present. Tracking these features can help distinguish stress urinary incontinence from other urinary patterns and show whether symptoms are genuinely changing over time.

Can a bladder diary help track Foundayo and urinary incontinence?

A bladder diary can help document urinary incontinence while someone is receiving Foundayo for an authorised indication. NICE recommends bladder diaries during the initial assessment of women with urinary incontinence because they provide information about urinary habits and leakage patterns.

The diary is not intended to measure whether Foundayo is “working” for bladder leakage. Instead, it creates a record of continence symptoms while weight management and other treatments continue, making it easier to identify whether leakage is improving, remaining stable or becoming more troublesome.

What if bladder leakage improves while losing weight on Foundayo?

If bladder leakage improves while body weight decreases, the improvement should be interpreted carefully. In trial reporting, women in perimenopause lost 14.4% of body weight with Foundayo, but that body weight change still does not show direct treatment of bladder leakage. NICE recognises that weight loss can help urinary incontinence in women living with obesity, so weight change may be clinically relevant to the improvement.

However, this does not demonstrate that Foundayo directly treated stress urinary incontinence. Other factors may change simultaneously, including pelvic floor muscle function, physical activity and established continence management. The medicine's authorised purpose remains separate from treatment directed specifically at urinary leakage.

What if Foundayo urinary incontinence symptoms do not improve?

Urinary incontinence does not have to improve simply because someone is losing weight with Foundayo. Weight management may help some people, but bladder leakage can have different contributing factors and may require treatment specifically directed at the type of incontinence present.

If symptoms remain troublesome, continue appropriate continence assessment rather than assuming more weight loss will necessarily resolve them. Persistent stress urinary incontinence can require supervised pelvic floor muscle training and further review according to individual circumstances.

Can Foundayo make urinary incontinence worse?

The official UK Foundayo authorisation information used for this article does not establish urinary incontinence as a characteristic effect of the medicine. A new or worsening leakage pattern during treatment should therefore not automatically be attributed to Foundayo. Common side effects of Foundayo are gastrointestinal-related and are not the same as established urinary incontinence effects. These can include nausea, bloating, diarrhea, and sometimes stomach pain, and they are usually temporary and improve over time.

Record when the change began and whether urinary urgency, discomfort or other new symptoms are present. A healthcare professional can review the symptom pattern, medicines and other possible contributing factors instead of assuming that the timing proves causation.

Why is the type of urinary incontinence important?

Different types of urinary incontinence can require different management. Stress urinary incontinence is characterised by leakage associated with increased abdominal pressure, while urgency incontinence involves leakage associated with a compelling need to pass urine.

Mixed urinary incontinence contains features of both patterns. This distinction matters when considering searches for Foundayo urinary incontinence because a weight-management medicine cannot replace assessment of which type of bladder leakage is actually occurring.

Does Foundayo for bladder leakage replace bladder training?

No. Foundayo is not authorised as a bladder-leakage treatment and should not replace bladder training when bladder training is clinically appropriate. NICE recommends bladder training as a first-line treatment for women with urgency or mixed urinary incontinence.

Stress urinary incontinence has a different first-line approach, centred on supervised pelvic floor muscle training. Correctly identifying the urinary pattern therefore matters before deciding which established management approach is relevant.

Can pelvic floor muscle training still help during weight management?

Yes. Weight management and pelvic floor muscle training can address different aspects of care at the same time. NICE recommends supervised pelvic floor muscle training as first-line treatment for women with stress or mixed urinary incontinence. During weight-management treatment, healthcare providers may also recommend consistent nutrition and a healthy diet to help manage side effects.

Weight loss, where appropriate, can be considered alongside this rather than instead of it. Someone receiving Foundayo for an authorised weight-management indication should not abandon established continence treatment because body weight is also being addressed. Strength training may also be advised during treatment to help prevent muscle loss.

Should Foundayo be started specifically because of bladder leakage?

No. Bladder leakage alone is not an authorised indication for Foundayo. Foundayo prescribing should be based on its authorised uses and the individual's clinical eligibility rather than the expectation that it will directly treat urinary incontinence.

Someone with both obesity and urinary incontinence may have overlapping management goals because NICE recognises weight loss as potentially helpful for urinary symptoms. That overlap does not turn stress urinary incontinence into a separate Foundayo indication.

When should changing bladder leakage be medically assessed?

New, persistent or substantially changing bladder leakage should be assessed according to the complete urinary symptom pattern. Do not assume that a change is simply a consequence of body weight or Foundayo treatment.

Tell a healthcare professional if the nature of the leakage changes, urinary symptoms become difficult to manage or new symptoms develop. Appropriate assessment can help identify the type of urinary incontinence and whether another explanation needs consideration.

What is the main answer about Foundayo for stress urinary incontinence?

Foundayo is not currently authorised to treat stress urinary incontinence or bladder leakage. Its authorised role is in weight management and type 2 diabetes, depending on the relevant regulatory indication.

There is an emerging research connection: orforglipron is currently being studied in a Phase 3 trial involving women with stress urinary incontinence who are overweight or obese. Until the trial produces evidence and any relevant regulatory authorisation is granted, it should not be described as an established treatment for SUI.

NICE also recognises that weight loss can help urinary incontinence in women with a BMI over 30, but recommends that other appropriate pelvic-floor management should not be delayed.

Medical Disclaimer

This article provides general information about Foundayo, stress urinary incontinence, weight management and bladder leakage. It does not establish Foundayo as a urinary incontinence treatment or recommend using it specifically for bladder symptoms.

Foundayo suitability depends on the individual's clinical circumstances, authorised indication, contraindications and other relevant safety information. Particular attention should be paid to the product information concerning personal or family history of medullary thyroid carcinoma. Persistent, new or changing urinary leakage should be assessed appropriately. Do not use Foundayo specifically for bladder symptoms or change prescribed treatment without speaking with a healthcare professional.